Synonyms: GRT 6005 | GRT-6005 | GRT6005
Compound class:
Synthetic organic
Comment: This compound is a novel benzenoid opioid analgesic [2-3,5], being assessed in clinical trials for various acute and chronic pain conditions. The compound is non-selective, acting at more than one member of the opioid receptor family [1,4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Cebranopadol advanced to Phase 3 clinical trial in patients with cancer-associated pain. However, Phase 3 study NCT01964378 was terminated due to an unworkable patient accrual rate. Phase 2 studies in other types of pain have been completed (click here to link to ClinicalTrials.gov's list of cebranopadol (GRT6005) trials). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01964378 | CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer | Phase 3 Interventional | Grünenthal GmbH |